Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...

Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...

Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...

Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...

As we are a pretty opinionated bunch here at PharmaTimes, we like it when contributors are prepared to stand up and express a viewpoint. For the past few months, our expanded SmartViews section has ...

Market access and a greater focus on specialist medicines are key to Takeda UK’s drive to be best in class for employees and customers ...